6-A Y							mplete if Known		
Substitute for form 1449A/PTO					Application Number		10/595,656		
INFORMATION DISCLOSURE					Filing Date		y 3, 2007	<u> </u>	
STATEMENT BY APPLICANT					med Inventor		(empers	- <u></u>	
			•	Art Unit		1623			
<u>~2~</u>	(Use	as many sheets as necessary)			Examiner Name				
Sheet 1	<u> </u>	of 2		Attorne	Attorney Docket Number		C 2903 PCT/US		
			U. S.	PATENT D	OCUMENTS				
Examiner Initials*	Cite No.1	Document Number		ation Date	Name of Patent		Pages, Columns, Lines, Where Relevant		
# Nite 15	NO.	Number-Kind Code <sup>2(8 known)</sup>		D-YYYY-0i	Applicant of Cited D	plicant of Cited Document Passages or Figure			
		US-6,153,594	11-28	-2000	Boerretzen et al.				
		US-6,348,451	02-19	-2002	Von Borstel Reid et al.	/on Borstel Reid Warren			
		US-20020035086	03-21	-2002	von Borstel et al.	von Borstel et al.			
		US-6,258,795	07-10	-2001	von Borstel et al.				
		US-6,274,563	08-14	-2001	von Borstel et al.				
		US-6,316,426	11-13	-2001	von Borstel et al.				
		US-5,470,838	11-28	-1995	von Borstel et al.				
	_	US-5,583,117	12-10	-1996	von Borstel et al.				
		US-							
	_	US-							
	_	US-			· · · · · · · · · · · · · · · · · · ·				
		US-							
		US-							
	_	US-							
		US-							
		US-							
			·						
Examiner	Cite	Foreign Retest Downwest		Publication	Name of Patente			Pages, Columns,	
Initials*	No.1			Date MM-DD-YYY	Applicant of Cited			Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		GB 1 297 398	11-22		-22-1972 Takeda			I igul ee / ppcai	
		EP 0 450 102		10-09-199		Yamasa Shoyu Kabushiki Kaisha			
		WO 02/088159		11-07-200	2 Rudy Susilo	Rudy Susilo			
		WO 89/03837		05-05-198	9 Pro-Neuron, I	Pro-Neuron, Inc.			
		EP 0 339 075 (abstract) (equiv. to WO89/03837)		05-05-198	9 Pro-Neuron, I	Pro-Neuron, Inc.			
				07-17-200	3 Innovate Biot	Innovate Biotechnology S.R.I.			
									T
					<del>-   · · · </del>			<del>                                     </del>	<del>1</del>

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Certification from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date Considered

Examine

Signature

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Complete if Known			
Substitute for form 1449A/PTO	Application Number	10/595,656		
INFORMATION DISCLOSURE	Filing Date	January 3, 2007		
	First Named Inventor	Peter Kempers		
STATEMENT BY APPLICANT	Art Unit	1623		
(Use as many sheets as necessary)	Examiner Name			
Sheet 2 of 2	Attorney Docket Number	C 2903 PCT/US		

Evaminer	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,	1		
Examiner Cite No. 1		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Krauch et al., "Synthesis and behaviour of nucleoside surface-active derivatives in monolayers", COLLOIDS AND SURFACES, 1991, vol.57, pgs 383-391. XP-002317768			
		Zinni et al., "Regioselective preparation of 2', 3'-di'O-acylribonucleosides carrying lipophilic acyl groups through a lipase-catalysed alcoholysis", BIOTECHNOLOGY LETTERS, 2002, vol.24, pgs 979-983. XP-002317769			
		Yun et al., "Novel thymidine-based organogelators and their gelation behaviours", CHEM. COMMUN., 2003, pgs 254-255. XP-002317770			
		Li et al., "Molecular Recognition Capabilities of a Nucleolipid Amphiphile (3',5'-Distearoyl)-2'-Deoxythymidine to Adenosine at the Air/Water Interface and Langmuir-Blodgett Films Studied by Molecular Spectroscopy", LANGMUIR, 2000, 16, pgs 7701-7707. XP-002317771			
		Morls et al., "A Useful and Versatile Procedure for the Acylation of Nucleosides through an Enzymatic Reaction", J. Org. Chem., 1993, vol.58, pgs 653-660. XP-002212949			
		Hammel et al., "Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system", Chemistry and Physics of Lipids, 2003, 123, pgs 193-207. XP-002317773			
		Huang et al., "Synthesis of Novel Nucleolipid Amphiphiles", Synthetic Communications, 1997, 27(4), pgs 681-690. XP009044059			
		Parang et al., "Syntheses and biological evaluation of 5'-O-myristoyl derivatives of thymidine against human immunodeficiency virus", Antiviral Chemistry & Chemotherapy, 1997, 8(5), pgs 417-427. XP009044063			
		Nishino et al., "Partial Protection of Carbohydrate Derivatives. Part 18, Simple, preparative procedure for 5'-O-Acylribonucleosides; Highly Regioselective O-Deacylation at 2' and 3' Positions of Fully Acylated Purine and Pyrimidine Ribonucleoside Through Sodium Methoxide - THF System", Tetrahedron, 1985, vol.41, pgs 5503-5506.			
		Uemura et al., "Lipase-catalyzed Regioselective Acylation of Sugar Moieties of Nucleosides", Tetrahedron Letters, 1989, vol.30, pgs 3817-3818.			
		Ozaki et al., "Enzyme Aided Regioselective Acylation of Nucleosides", Nucleosides & Nucleotides, 1995, 14(3-5), pgs 401-404.			
		Ozaki et al., "Enzyme aided regio-selective acylation and dacylation of nucleosides", Oxford Univ. Press, 1993, pgs 53-54.			
		Singh et al., "Manipulation of Enzyme Regioselectivity by Solvent Engineering: Enzymatic Synthesis of 5'-O-Acylribonucheosides", Tetrahedron Letters, 1994, vol.35, pgs 1353-1356.			
		Riva et al., "Protease-Catalyzed Regioselective Esterification of Sugars and Related Compounds in Anhydrous Dimethylformamide", J.Am.Chem.Soc., 1988, 110, pgs 584-589.			
		Cosmetics Directive (Die Kosmetik-Verordnung), Deutsches Institut fur Koerperpflege und Hygiene e.V., Annex 6, Parts A and B	1		
		Bradford, Marion M., "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Analytical Biochemistry, 1976, vol. 72, pgs 248-254.			

Examiner Signature		 Date	
Signature	]	Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

of this form with field communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C, 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.